NCT00989001View on ClinicalTrials.gov

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

PHASE3TerminatedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Atrial Fibrillation
Interventions
DRUG

Vernakalant

Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes

DRUG

Placebo

Injection

Sponsors

Lead Sponsor

Advanz Pharma
All Listed Sponsors
lead

Advanz Pharma

INDUSTRY